November 7, 2009
Abuse, Antidepressants, Antipsychotic, Big Pharma, Fraud, GlaxoSmithkline, News, Paxil, Psychiatrist
No Comments
BY JOHN DORSCHNER
jdorschner@MiamiHerald.com
Charles Nemeroff, an Atlanta psychiatrist who was the subject of a Senate investigation concerning huge sums he received from drug companies, has been named chairman of the psychiatry department at the University of Miami.
Last year Nemeroff, as the top psychiatrist at Emory University, was the focus of an investigation by Sen. Charles Grassley, R-Iowa, who said he was concerned about the millions the psychiatrist received from drug companies while conducting supposedly unbiased research for the National Institutes of Health on drugs made by the companies he was receiving money from.
On Thursday, Pascal Goldschmidt, dean of UM medical school, called Nemeroff “an exceptional psychiatrist and an exceptional scientist who has one issue in which he recognizes he made a mistake,” in not telling Emory how much he was getting from drug makers.
Goldschmidt said he had read investigative reports from Emory about Nemeroff’s activities and Emory found nothing to indicate that payments the psychiatrist received had in any way influenced his research results.
Read the rest…
August 31, 2009
Antidepressants, Antipsychotic, Big Pharma, Fraud, Human rights, Psychotropic drugs, Videos
No Comments
Whistleblower Allen Jones gained international press coverage after uncovering pharmaceutical industry payments to government officials for the purpose of implementing a national mental health screening/psychotropic drug treatment plan. In this video interview Jones describes the pharma funding and psycho/pharma agenda behind mental health “screening” of schoolchildren. He is a former investigator for the Pennsylvania Office of the Inspector General.
[youtube]http://www.youtube.com/watch?v=7GhBfDMW2Fo[/youtube]
For more information go to
http://www.cchrint.org/2009/08/26/teen-screen-cynical-deception-dangerous-illusion/
August 13, 2009
Antidepressants, Antipsychotic, Big Pharma, Eli Lilly, Psychiatrist, Psychiatry, Psychotropic drugs
2 Comments
Shane Ellison has a masters degree in organic chemistry and is a two-time recipient of the prestigious Howard Hughes Medical Institute Research Grant for his studies in biochemistry and physiology. Here Shane exposes the inner workings of the psycho/pharmaceutical industry, the manufacture and marketing of psychiatric drugs and the fact that the psycho/pharma industry is well aware their drugs do not cure anyone. He previously worked for both Array BioPharma and Eli Lilly.
[youtube]http://www.youtube.com/watch?v=fOT5DSIUTOY[/youtube]
August 13, 2009
Abuse, Antidepressants, Antipsychotic, Big Pharma, Drug-induced suicide, FDA, Fraud, News, Psychiatry, Psychotropic drugs
No Comments
BY CAROL MARBIN MILLER
cmarbin@MiamiHerald.com
Admitting for the first time what critics have claimed for years, state child-welfare authorities say caregivers for children in state custody frequently use powerful mind-altering drugs to manage unruly kids, rather than treat their anger and sadness.A panel of child-welfare experts, including two top administrators from the state Department of Children & Families, examined the death of a 7-year-old Broward foster child who was on psychotropic medications — without the required consent — when he hanged himself in a Margate home.
The panel’s report, expected to be released publicly later this month, says child welfare authorities too often rely on the potent medications to manage abused and neglected children — but fail to offer psychiatric treatment to help them overcome the trauma they suffered.
Read the rest…
April 28, 2009
ADD, ADHD, Antidepressants, Antipsychotic, Anxiety, Big Pharma, Bipolar, DSM, Fraud, Psychiatry, Videos
No Comments
The essentials differences between a biological diseases and a mental disorder.
[youtube]http://www.youtube.com/watch?v=n3JQ8OVHVWA[/youtube]
April 28, 2009
Abuse, Antidepressants, Antipsychotic, Drug-induced suicide, FDA, Fraud, News, Psychiatry, Symbyax
No Comments
By Jon Burstein
April 24, 2009
MARGATE – State officials are investigating whether a 7-year-old boy who hanged himself in his Margate foster home had been given a powerful, mind-altering drug in violation of Florida law.
Three weeks before his April 16 suicide, Gabriel Myers was prescribed the drug Symbyax, which is a combination of the generic forms of the anti-depressant Prozac and the anti-psychosis drug Zyprexa, according to state Department of Children & Families records released Friday night.
But there was no court order in place for Gabriel to use the drug, the records show. Under Florida law, parental consent or a judge’s ruling is needed before a foster child can be administered a psychotropic drug.
Read the rest…
April 6, 2009
Antidepressants, Antipsychotic, Big Pharma, Death, FDA, Fraud, Lexapro, Prozac, drug-induced school shootings, effexor
No Comments
The Winnendon, Germany school shooting, which left 17 dead including the gunman, appears to be the latest in the chain of psychiatric drug-induced school shootings. A March 15 article in Scotland on Sunday, revealed that the shooter, Tim Kretschmer, “had been suffering from depression, even attending a clinic and receiving medication for the condition.”
With casualties from school or teen shootings now totaling 54 dead and 105 wounded, the mental health watchdog Citizens Commission on Human Rights (CCHR) says it is time to stop vested interests from spouting their usual propaganda about psychiatric drugs, and instead demand a federal investigation for the sake of public safety.
Read the rest…
March 10, 2009
Abuse, Antipsychotic, Haldol (haloperidol), Hospital, Human rights, Important, Psychiatry, Videos, unhappy patients
No Comments
“Inside Outside” is a work of hope created by former patients and film-makers Pat Deegan and Terry Strecker. The film depicts the lives of eight people with very significant histories of institutionalization, as they transition from nursing homes and psychiatric hospitals into the community. In the spirit of the President’s New Freedom Initiative and the Supreme Court’s Olmstead Decision, the film carries the message that recovery and life in the community are possibilities even for people who are viewed as the most chronic or impaired. The film leaves audiences of professionals and people with psychiatric disabilities alike, cheering for these eight individuals as they make their journey from inside institutions to full community inclusion on the outside. Produced for the US Department of Health And Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services. This is Part 1 of 2 parts. Producer: Pat Deegan, Ph.D and Terry Strecker
Production Company: Advocates for Human Potential, Inc. Creative Commons license: Public Domain.
PART 1
[youtube]http://www.youtube.com/watch?v=IJ-udSAzbbM[/youtube]
PART 2
[youtube]http://www.youtube.com/watch?v=Q6DnRvbgvjw[/youtube]
March 8, 2009
Antipsychotic, AstraZeneca, FDA, Fraud, News, Psychiatry, Seroquel, unhappy patients
1 Comment
By Miriam Hill |Inquirer Staff Writer
Shortly after new antipsychotic drugs came on the market in the late 1990s, the Food and Drug Administration started to worry that they might trigger diabetes in some patients.
So in 2000, the FDA asked AstraZeneca P.L.C. and other pharmaceutical companies to share data on cases of new-onset diabetes and related illnesses in patients taking the drugs. London-based AstraZeneca, which has U.S. headquarters in Wilmington, told the FDA that patients and doctors had reported 12 new cases of diabetes and five cases of related illnesses among the 623,000 who had taken its antipsychotic drug Seroquel.
Read the rest…
March 3, 2009
Antipsychotic, AstraZeneca, FDA, Fraud, News, Psychiatry, Seroquel
No Comments
WASHINGTON, March 3 (Reuters) – U.S. regulators will ask outside advisers for input on safety concerns surrounding expanded use of AstraZeneca Plc’s (AZN.L: Quote, Profile, Research, Stock Buzz) schizophrenia drug Seroquel XR, the Food and Drug Administration said on Tuesday.
The issues for discussion at the April 8 advisory panel meeting include “concerns regarding exposing a greatly expanded population to a drug with known metabolic side effects and a possible risk of tardive dyskinesia,” an FDA notice said.
Read the rest…
Loading ...